Lead Candidate

It's time for another quarterly look at what Lead Candidate have been working on over the last three months! Swipe below to have a nosey ...⬇️ We've had an exciting quarter supporting the growth of our partners. Whether they're scaling up or strengthening their teams, we're priviledged to be part of their journey. We're committed to playing a part in this ever-evolving industry and assisting both our existing and new partners in achieving their goals. Interested in finding out how we could help your organisation? 📩 Get in touch at apply@leadcandidate.com 📲 Or book a consultation call here: https://lnkd.in/di8RNERy #TalentPartner #TalentAcquisition #CDMO

Bruce Thompson, CEO at Kincell Bio, discusses key challenges in cell therapy development and actions #CDMOs can take to streamline this process 🔬 🤝 Bruce notes that early collaboration between research and development teams is critical to navigating complex decisions. He also highlights how breaking down the development journey into more managable steps using stage-gates can help streamline the process. ➡️ This article is the first in a two-part series and focuses on the initial stages of product development—specifically, how to move from candidate selection to a Phase 1 Investigational New Drug (IND) application. Access the article from Bioprocess Online below ⬇️ #CellTherapy #Biotech #Pharma #CDMO

OmniaBio announced the opening of the largest cell and gene therapy CDMO manufacturing facility in Canada! 🏢 The new 120,000 square-foot facility, based in Ontario, cost CAD 580 million to build and will create 250 jobs. 💬 Mitchel Sivilotti, CEO of OmniaBio, said: "This new facility puts us in a unique position as a specialist commercial CGT manufacturing leader tackling the toughest disease challenges head-on by combining an experienced team with advanced tools and solutions." He also praised the province for its talent pool and "academic institutions that are producing highly skilled staff that would go into either research or manufacturing." 🧑🔬 The facility will have a dedicated staff-training infrastructure and specialize in both cell and vector-focused manufacturing using robotics, biosensors, and machine learning technologies while supporting needs such as critical cold-chain logistics. 🤝 The facility's first commercial project will be for South Korean stem-cell therapeutics developer Medipost to manufacture its allogeneic umbilical-cord-blood-derived mesenchymal stem cell (MSC) product CARTISTEM, which is used to treat patients with osteoarthritis caused by degeneration. Congratulations to Mitchel and the OmniaBio team! 👏 #CDMO #CGT #CellandGeneTherapy

CDMO Rentschler Biopharma sets out on 3-year expansion of German HQ site 📈 ➡️ The 34,000-square-meter expansion will allow for the addition of a four-story buffer media station. Rentschler plans to add three media tanks and six buffer tanks that will be used to produce a uniform solution for drug compounds. 🏗️ Construction is slated to begin by spring 2025 and the expansion should be fully operational by 2028. 💬 "While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy," Benedikt von Braunmühl, Rentschler's chief executive, said in a release. #CDMO #Biopharma #PharmaNews

🔎 Process Technology Manager 📍 Norwich, NY We're looking for a driven innovator, passionate about continously improving the delivery of products and processes for customers. The Process Technology Manager will be responsible for leading the technical operations at the Norwich, NY site for a global nutrition company, providing ingredients for the food, beverage and pharmaceutical industries. Interested? ➡️ Find out more on our website: https://lnkd.in/eq7yE3hr 📧 Or send your resume to matt@leadcandidate.com to apply If you know someone who would be perfect to take on this opportunity, we want to hear from you! 👂🏻 #ProcessTechnology #ProcessTech #NorwichJobs

NorthStar Medical Radioisotopes, LLC, a radiopharmaceutical CDMO, has officially opened its new Dose Manufacturing Center in Beloit, Wisconsin! ➡️ The state-of-the-art facility will increase NorthStar's capacity to support biopharmaceutical companies in the development and production of critical radioisotopes used for therapeutic and diagnostic purposes. 💬 Dr. Frank Scholz, President and CEO of NorthStar, said, "NorthStar has evolved into a company capable of developing, producing, and delivering a broad range of pharmaceuticals from one integrated campus. Our facility is purpose-built for scalability, reliability, and safety, which enables us to meet the increasing needs of our customers." Congratulations to the team at NorthStar! 🙌 #CDMO #Radiopharmaceutical #Radiopharma

Happy Mole Day! 🧪 Today is a day all about honouring Avogadro's Number (6.02 x 10²³) and it happens to fall right in the middle of Chemistry Week 👩🔬 Working in the CDMO space, we know our chemistry. But beyond organic synthesis and HPLC, we understand that in a hard skills focused industry, having the perfect mix of cultural chemistry can go a long way. Scroll below to see how chemistry can impact the hiring process for the better ➡️ Think we have chemistry? Get in touch to see how we could help fuel your growth: 📧 Email us at apply@leadcandidate.com 📲 Book a discovery call here: https://lnkd.in/di8RNERy #CDMO #CRO #Pharma #TalentPartner

CDMO Nucleus RadioPharma reveals expansions at two sites that will "significantly improve" market access to promising cancer treatments. 🏗️ The upgrades at sites in Mesa, Arizona and Springhouse, Pennsylvania will give each facility research, development and commercial production capabilities, boosting capacity by 200%. The expansions are expected to be completed by the end of 2026 and will create around 100 jobs overall. 💉 The upgrades will allow more patients to receive radiopharmaceuticals, which have a limited shelf-life, according to Nucleus. 💬 "To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them," Nucleus RadioPharma CEO Charles Conroy, RPh, MBA said in a release. "Our expansion will significantly improve patient access to these life-saving treatments and expedite clinical trials, potentially reducing time-to-market for new therapies by up to 30%." #CDMO #Radiopharmaceuticals #Radiopharma

We're looking for another Talent Partner to join the Lead Candidate team and help support our partners in the pharma and bio outsourcing space! No recruitment experience needed, this is an entry-level position. All we ask is that you will relish the opportunity to learn and grow with us as we disrupt the recruitment industry for the better. 💷 £24,000 - £28,000 📍Newcastle Upon Tyne / Hybrid Check out the full job ad below ⬇️ #TalentPartner #TalentAcquisition #NorthEastJobs

Lonza has completed its 6000m² expansion at its drug product services (DPS) site in Basel, Switzerland. 📈 The expansion has extended its DPS offering by adding a new facility for QC and bioanalytics, supporting both clinical and commercial projects. 💬 Peter Droc, Head of Drug Product Services at Lonza, said, "Expanding Lonza's drug product capacity is a key enabler of our wider Biologics strategy to offer drug developers a seamless solution across modalities, from early development to drug substance and drug product manufacture." Congratulations to the Lonza team! 🙌